UPDATED APRIL 7 TO INCLUDE NEW IPR: Hayman Capital’s Kyle Bass and IP Nav’s Erich Spangenberg have targeted a second and third pharmaceutical company at the PTAB, filing inter partes review petitions challenging patents owned by Shire and Jazz
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
As trade secret filings rise due to AI development and economic espionage concerns, firms are relying on proactive counselling to help clients navigate disputes
IP firm leaders share why they remain positive in the face of falling patent applications from US filers, and how they are meeting a rising demand from China